Commercial antidiabetic polyherbal formulations (APH) are available with claimed hypoglycemic activities; yet they lack systematic scientific studies leading to their limited global acceptance. In the present study, six selected APH from the Indian market were evaluated for their phytochemical contents, anti-hyperglycemic, anti-hyperlipidemic, antioxidant activities and further identifying the major antidiabetic bioactive compound of “MA” by HPLC–ESI–MS/MS. Our results revealed highest TPC (136.97 ± 0.6 µg GAE/mg) and TFC (128.85 ± 0.74 µg QE/mg) in APH-DB and APH-SN, respectively. APH-MA has exhibited highest α-amylase 72.5% (IC50-579.65 μg/ml), α-glucosidase 88.02% (IC50-261.03 μg/ml) and moderate lipase inhibition 57.7% (IC50 159.57 μg/ml). A variable free radical scavenging activity was observed by all the tested APH. Further significant linear positive correlations were observed between TPC-Lipase (r2-0.985****), TFC-α-amylase (r2-0.868**) and DPPH-α-amylase inhibition (r2-0.8098*). HPLC–ESI–MS/MS of MA showed the presence of anti-hyperglycemic compounds, Pheophorbide a and Pyropheophorbide a, as the major peaks. Among the tested extracts, MA exhibited better activities while BG, MH, SN, DB, and DT have showed comparable/mild anti-hyperglycemic, anti-hyperlipidemic and antioxidant potential. Hence the tested APH may be considered effective for DM management which can further be assessed for their other targets of inhibition.
Keywords: Antioxidant, Correlation, Hyperglycemic, Hyperlipidemic, HPLC–ESI–MS/MS, Polyherbal formulations
small logo
Current Preprint Count
16,731
How to Use
Click on "Archives" to access the full archive of scientific preprints. You may use the categories and the search functionality to find select preprints you're interested in.
